These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 18690012

  • 1. Development of an HPV vaccine for a broad spectrum of high-risk types.
    Kanda T, Kondo K.
    Hum Vaccin; 2009; 5(1):43-5. PubMed ID: 18690012
    [Abstract] [Full Text] [Related]

  • 2. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M, Fochesato M, Miseur A, Mertens E, Dendouga N, Brendle S, Balogh KK, Christensen ND, Giannini SL.
    J Virol; 2016 Jul 15; 90(14):6314-25. PubMed ID: 27147749
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
    Kondo K, Ochi H, Matsumoto T, Yoshikawa H, Kanda T.
    J Med Virol; 2008 May 15; 80(5):841-6. PubMed ID: 18360909
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
    Wu WH, Alkutkar T, Karanam B, Roden RB, Ketner G, Ibeanu OA.
    Virol J; 2015 Sep 11; 12():140. PubMed ID: 26362430
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.
    Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, Faust H, Dillner J, Roden RBS, Kirnbauer R.
    J Invest Dermatol; 2013 Dec 11; 133(12):2706-2713. PubMed ID: 23752042
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
    Zhai L, Yadav R, Kunda NK, Anderson D, Bruckner E, Miller EK, Basu R, Muttil P, Tumban E.
    Antiviral Res; 2019 Jun 11; 166():56-65. PubMed ID: 30926288
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
    Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RB.
    J Natl Cancer Inst; 2009 Jun 03; 101(11):782-92. PubMed ID: 19470949
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.